NF-κB Is a Negative Regulator of IL-1β Secretion as Revealed by Genetic and Pharmacological Inhibition of IKKβ

Cell

Volumn 130, Issue 5, 2007, Pages 918-931

  Greten, Florian R ^a,c   Arkan, Melek C ^a,c   Bollrath, Julia ^a   Hsu, Li Chung ^c   Goode, Jason ^c   Miething, Cornelius ^a   Göktuna, Serkan I ^a   Neuenhahn, Michael ^b   Fierer, Joshua ^d   Paxian, Stephan ^a   Van Rooijen, Nico ^e   Xu, Yajun ^f   O'Cain, Timothy ^f   Jaffee, Bruce B ^f   Busch, Dirk H ^b   Duyster, Justus ^a   Schmid, Roland M ^a   Eckmann, Lars ^d   Karin, Michael ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

^f MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

MOLIMMUNO; SIGNALING

Indexed keywords

I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; ML 120B; SERINE; UNCLASSIFIED DRUG; CARBOLINE DERIVATIVE; DRUG DERIVATIVE; I KAPPA B KINASE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE, ESCHERICHIA COLI 0111 B4; MESSENGER RNA; N (6 CHLORO 7 METHOXY 9H BETA CARBOLIN 8 YL) 2 METHYLNICOTINAMIDE; N-(6-CHLORO-7-METHOXY-9H-BETA-CARBOLIN-8-YL)-2-METHYLNICOTINAMIDE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL INFECTION; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG INHIBITION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MOUSE; NEUTROPHIL; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SEPTIC SHOCK; ANIMAL; APOPTOSIS; BLOOD; CELL LINE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; SECRETION; TIME;

BACTERIA (MICROORGANISMS); MUS;

ANIMALS; APOPTOSIS; CARBOLINES; CASPASE 1; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; NEUTROPHILS; NF-KAPPA B; NIACINAMIDE; PROTEIN KINASE INHIBITORS; RECEPTORS, INTERLEUKIN-1; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SERPINS; SHOCK, SEPTIC; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548225362     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2007.07.009     Document Type: Article

References (55)

1. Algül H., Treiber M., Lesina M., Nakhai H., Saur D., Geisler F., Pfeifer A., Paxian S., and Schmid R.M. Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. J. Clin. Invest. 117 (2007) 1490-1501
2. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., Wynshaw-Boris A., Poli G., Olefsky J., and Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11 (2005) 191-198
3. Black R.A., Kronheim S.R., Cantrell M., Deeley M.C., March C.J., Prickett K.S., Wignall J., Conlon P.J., Cosman D., Hopp T.P., et al. Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor. J. Biol. Chem. 263 (1988) 9437-9442
4. Bonizzi G., and Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25 (2004) 280-288
5. Bruey J.M., Bruey-Sedano N., Luciano F., Zhai D., Balpai R., Xu C., Kress C.L., Bailly-Maitre B., Li X., Osterman A., et al. Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1. Cell 129 (2007) 45-56
6. Chen L.W., Egan L., Li Z.W., Greten F.R., Kagnoff M.F., and Karin M. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat. Med. 9 (2003) 575-581
7. Clausen B.E., Burkhardt C., Reith W., Renkawitz R., and Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8 (1999) 265-277
8. Coeshott C., Ohnemus C., Pilyavskaya A., Ross S., Wieczorek M., Kroona H., Leimer A.H., and Cheronis J. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc. Natl. Acad. Sci. USA 96 (1999) 6261-6266
9. Cohen J. The immunopathogenesis of sepsis. Nature 420 (2002) 885-891
10. Dinarello C.A. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112 (1997) 321S-329S
11. Dinarello C.A. Interleukin-1beta. Crit. Care Med. 33 (2005) S460-S462
12. Dinarello C.A., Cannon J.G., Mier J.W., Bernheim H.A., LoPreste G., Lynn D.L., Love R.N., Webb A.C., Auron P.E., Reuben R.C., et al. Multiple biological activities of human recombinant interleukin 1. J. Clin. Invest. 77 (1986) 1734-1739
13. Fantuzzi G., Ku G., Harding M.W., Livingston D.J., Sipe J.D., Kuida K., Flavell R.A., and Dinarello C.A. Response to local inflammation of IL-1 beta-converting enzyme- deficient mice. J. Immunol. 158 (1997) 1818-1824
14. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl (2002) S81-S96
15. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., and Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
16. Hazuda D.J., Strickler J., Kueppers F., Simon P.L., and Young P.R. Processing of precursor interleukin 1 beta and inflammatory disease. J. Biol. Chem. 265 (1990) 6318-6322
17. Hogquist K.A., Nett M.A., Unanue E.R., and Chaplin D.D. Interleukin 1 is processed and released during apoptosis. Proc. Natl. Acad. Sci. USA 88 (1991) 8485-8489
18. Horwitz B.H., Scott M.L., Cherry S.R., Bronson R.T., and Baltimore D. Failure of lymphopoiesis after adoptive transfer of NF-kappaB-deficient fetal liver cells. Immunity 6 (1997) 765-772
19. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348 (2003) 138-150
20. Humke E.W., Shriver S.K., Starovasnik M.A., Fairbrother W.J., and Dixit V.M. ICEBERG: a novel inhibitor of interleukin-1beta generation. Cell 103 (2000) 99-111
21. Irmler M., Hertig S., MacDonald H.R., Sadoul R., Becherer J.D., Proudfoot A., Solari R., and Tschopp J. Granzyme A is an interleukin 1 beta-converting enzyme. J. Exp. Med. 181 (1995) 1917-1922
22. Kannan-Thulasiraman P., and Shapiro D.J. Modulators of inflammation use nuclear factor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9. J. Biol. Chem. 277 (2002) 41230-41239
23. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3 (2002) 221-227
24. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3 (2004) 17-26
25. Karin M., Lawrence T., and Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124 (2006) 823-835
26. Kisseleva T., Song L., Vorontchikhina M., Feirt N., Kitajewski J., and Schindler C. NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. J. Clin. Invest. 116 (2006) 2955-2963
27. Kuhn R., Schwenk F., Aguet M., and Rajewsky K. Inducible gene targeting in mice. Science 269 (1995) 1427-1429
28. Kuida K., Lippke J.A., Ku G., Harding M.W., Livingston D.J., Su M.S., and Flavell R.A. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267 (1995) 2000-2003
29. Lee E.G., Boone D.L., Chai S., Libby S.L., Chien M., Lodolce J.P., and Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289 (2000) 2350-2354
30. Li P., Allen H., Banerjee S., Franklin S., Herzog L., Johnston C., McDowell J., Paskind M., Rodman L., Salfeld J., et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80 (1995) 401-411
31. Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2 (2002) 725-734
32. Liu Z., Zhou X., Shapiro S.D., Shipley J.M., Twining S.S., Diaz L.A., Senior R.M., and Werb Z. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102 (2000) 647-655
33. Maeda S., Kamata H., Luo J.L., Leffert H., and Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
34. Martinon F., and Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117 (2004) 561-574
35. Martinon F., Burns K., and Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10 (2002) 417-426
36. McIntyre K.W., Shuster D.J., Gillooly K.M., Dambach D.M., Pattoli M.A., Lu P., Zhou X.D., Qiu Y., Zusi F.C., and Burke J.R. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 48 (2003) 2652-2659
37. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J., Young D.B., Barbosa M., Mann M., Manning A., and Rao A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278 (1997) 860-866
38. Miething C., Grundler R., Mugler C., Brero S., Hoepfl J., Geigl J., Speicher M.R., Ottmann O., Peschel C., and Duyster J. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc. Natl. Acad. Sci. USA 104 (2007) 4594-4599
39. Mizutani H., Schechter N., Lazarus G., Black R.A., and Kupper T.S. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J. Exp. Med. 174 (1991) 821-825
40. Nagashima K., Sasseville V.G., Wen D., Bielecki A., Yang H., Simpson C., Grant E., Hepperle M., Harriman G., Jaffee B., et al. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. Blood 107 (2006) 4266-4273
41. Ogura Y., Sutterwala F.S., and Flavell R.A. The inflammasome: first line of the immune response to cell stress. Cell 126 (2006) 659-662
42. Orth K., Xu Z., Mudgett M.B., Bao Z.Q., Palmer L.E., Bliska J.B., Mangel W.F., Staskawicz B., and Dixon J.E. Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease. Science 290 (2000) 1594-1597
43. Park J.M., Greten F.R., Wong A., Westrick R.J., Arthur J.S., Otsu K., Hoffmann A., Montminy M., and Karin M. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis-CREB and NF-kappaB as key regulators. Immunity 23 (2005) 319-329
44. Pham C.T. Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. Immunol. 6 (2006) 541-550
45. Ruocco M.G., Maeda S., Park J.M., Lawrence T., Hsu L.C., Cao Y., Schett G., Wagner E.F., and Karin M. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201 (2005) 1677-1687
46. Senftleben U., Li Z.W., Baud V., and Karin M. IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity 14 (2001) 217-230
47. Suffredini A.F., Reda D., Banks S.M., Tropea M., Agosti J.M., and Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J. Immunol. 155 (1995) 5038-5045
48. Taylor P.R., and Gordon S. Monocyte heterogeneity and innate immunity. Immunity 19 (2003) 2-4
49. Van Rooijen N., and Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174 (1994) 83-93
50. van Rooijen N., Bakker J., and Sanders A. Transient suppression of macrophage functions by liposome-encapsulated drugs. Trends Biotechnol. 15 (1997) 178-185
51. Vassiloyanakopoulos A.P., Okamoto S., and Fierer J. The crucial role of polymorphonuclear leukocytes in resistance to Salmonella dublin infections in genetically susceptible and resistant mice. Proc. Natl. Acad. Sci. USA 95 (1998) 7676-7681
52. Wegener E., Oeckinghaus A., Papadopoulou N., Lavitas L., Schmidt-Supprian M., Ferch U., Mak T.W., Ruland J., Heissmeyer V., and Krappmann D. Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation. Mol. Cell 23 (2006) 13-23
53. Wiesner O., Litwiller R.D., Hummel A.M., Viss M.A., McDonald C.J., Jenne D.E., Fass D.N., and Specks U. Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments. FEBS Lett. 579 (2005) 5305-5312
54. Zeng W., and Remold-O'Donnell E. Human monocyte/neutrophil elastase inhibitor (MNEI) is regulated by PU.1/Spi-1, Sp1, and NF-kappaB. J. Cell. Biochem. 78 (2000) 519-532
55. Zingarelli B. Nuclear factor-kappaB. Crit. Care Med. 33 (2005) S414-S416